Hyperthermic MMC—A Systematic Review

  • Sanchia S. GoonewardeneEmail author
  • Raj Persad
  • Hanif Motiwala
  • David Albala


A systematic review relating to hyperthermic MMC in NMIBC was conducted. This was to identify the oncological outcomes from with hyperthermic mitomycin C for NMIBC. This chapter covers systematic review results.


  1. Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009;27(3):319–24.CrossRefGoogle Scholar
  2. Arends TJ, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014;192(3):708–13.CrossRefGoogle Scholar
  3. Arends TJ, Falke J, Lammers RJ, Somford DM, Hendriks JC, de Weijert MC, Arentsen HC, van der Heijden AG, Oosterwijk E, Alfred Witjes J. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World J Urol. 2015;33(10):1411–7.CrossRefGoogle Scholar
  4. Ba M, Cui S, Wang B, Long H, Yan Z, Wang S, Wu Y, Gong Y. Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection. Oncol Rep. 2017;37(5):2761–70.CrossRefGoogle Scholar
  5. Bahouth Z, Halachmi S, Moskovitz B, Nativ O. The role of hyperthermia as a treatment for non-muscle invasive bladder cancer. Expert Rev Anticancer Ther. 2016;16(2):189–98.CrossRefGoogle Scholar
  6. Colombo R, Da Pozzo LF, Lev A, Salonia A, Rigatti P, Leib Z, Servadio C, Caldarera E. Pavone-Macaluso M Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable NMI bladder tumors. J Urol. 1998;159(3):783–7.CrossRefGoogle Scholar
  7. Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–8.CrossRefGoogle Scholar
  8. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, Vespasiani G. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk NMI bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777–82.CrossRefGoogle Scholar
  9. D’Souza N, Verma A. Holmium laser transurethral resection of bladder tumor: our experience. Urol Ann. 2016;8(4):439.CrossRefGoogle Scholar
  10. Ekin RG, Akarken I, Cakmak O, Tarhan H, Celik O, Ilbey YO, Divrik RT, Zorlu F. Results of Intravesical chemo-hyperthermia in high-risk non-muscle invasive bladder cancer. Asian Pac J Cancer Prev. 2015;16(8):3241–5.CrossRefGoogle Scholar
  11. Geijsen ED, de Reijke TM, Koning CC, Zum Vörde Sive Vörding PJ, de la Rosette JJ, Rasch CR, van Os RM, Crezee J. Combining mitomycin C and regional 70 MHz hyperthermia in patients with nonmuscle invasive bladder cancer: a Pilot study. J Urol. 2015;194(5):1202–8.Google Scholar
  12. Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade NMI bladder cancer. Urology. 2004;63(3):466–71.CrossRefGoogle Scholar
  13. Gözen AS, Umari P, Scheitlin W, Su FE, Akin Y, Rassweiler J. Effectivity of intravesical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer. Arch Ital Urol Androl. 2017;89(2):102–5.CrossRefGoogle Scholar
  14. Halachmi S, Moskovitz B, Maffezzini M, Conti G, Verweij F, Kedar D, Sandri SD, Nativ O, Colombo R. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol. 2011;29(3):259–64.CrossRefGoogle Scholar
  15. Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2014;30(3):171–5.CrossRefGoogle Scholar
  16. Kiss B, Schneider S, Thalmann GN, Roth B. Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer? Int J Urol. 2015;22(2):158–62.CrossRefGoogle Scholar
  17. León-Mata J, Domínguez JL, Redorta JP, Sousa González D, Alvarez Casal M, Sousa Escandón A, Piñeiro Vázquez E. Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer. Arch Esp Urol. 2018;71(4):426–37.Google Scholar
  18. Mays N, Pope C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Policy. 2005;10(Suppl. 1):6–20.CrossRefGoogle Scholar
  19. Milla P, Fiorito C, Soria F, Arpicco S, Cattel L, Gontero P. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in NMI transitional cell carcinoma patients. Cancer Chemother Pharmacol. 2014;73(3):503–9.CrossRefGoogle Scholar
  20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. BMJ. 2009;339(7716):332–6.CrossRefGoogle Scholar
  21. Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, Nativ O. Thermo-chemotherapy for intermediate or high-risk recurrent NMI bladder cancer patients. Ann Oncol. 2005;16(4):585–9.CrossRefGoogle Scholar
  22. Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R, Leibovitch I. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol. 2009;182(4):1313–7.CrossRefGoogle Scholar
  23. Rigatti P, Lev A, Colombo R. Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for NMI bladder tumors. A preliminary clinical study. Eur Urol. 1991;20(3):204–10.CrossRefGoogle Scholar
  24. Sooriakumaran P, Chiocchia V, Dutton S, Pai A, Ayres BE, Le Roux P, Swinn M, Bailey M, Perry MJ, Issa R. Predictive factors for time to progression after hyperthermic mitomycin C treatment for high-risk non-muscle invasive urothelial carcinoma of the bladder: an observational cohort study of 97 patients. Urol Int. 2016;96(1):83–90.CrossRefGoogle Scholar
  25. Sousa A, Piñeiro I, Rodríguez S, Aparici V, Monserrat V, Neira P, Carro E, Murias C, Uribarri C. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):374–80.CrossRefGoogle Scholar
  26. van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):351–62.Google Scholar
  27. Volpe A, Racioppi M, Bongiovanni L, D’Agostino D, Totaro A, D’Addessi A, Marangi F, Palermo G, Pinto F, Sacco E, Bassi PF. Thermochemotherapy for non-muscle-invasive bladder cancer: is there a chance to avoid early cystectomy? Urol Int. 2012;89(3):311–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
    Email author
  • Raj Persad
    • 2
  • Hanif Motiwala
    • 3
  • David Albala
    • 4
  1. 1.East of England DeaneryNorfolk and Norwich University HospitalNorwichUK
  2. 2.North Bristol NHS TrustBristolUK
  3. 3.Southend University HospitalWestcliff-on-SeaUK
  4. 4.Boston UniversityBostonUSA

Personalised recommendations